Company intelligence / Profile preview

Elwick Lifesciences

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Elwick Lifesciences is a UK-based biotechnology company focused on developing novel small molecule therapeutics that modulate the Integrated Stress Response (ISR). The company's primary focus is on targeting the eIF2B complex to treat neurodegenerative disorders and certain types of cancer. By restoring protein synthesis in stressed cells, Elwick aims to address the underlying pathology of diseases such as Vanishing White Matter Disease and Amyotrophic Lateral Sclerosis. The company leverages deep expertise in ISR biology to advance a pipeline of potent and selective eIF2B activators.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Elwick Lifesciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elwick Lifesciences.

Explore the full profile